Home Health News Moderna to develop vaccine candidates for seasonal flu, HIV – MarketWatch

Moderna to develop vaccine candidates for seasonal flu, HIV – MarketWatch

2 min read
1
5

Shares of Moderna Inc.
MRNA,
+3.97%

were up 1.3% in premarket trading on Monday after the company said it plans to launch new development programs using its mRNA technology that will focus on developing vaccines for seasonal flu, HIV, and the Nipah virus. This follows the success of its mRNA COVID-19 vaccine, which is one of two vaccines to be authorized so far in the U.S. CEO Moderna also said it plans to expand its respiratory syncytial virus to include older adults, and it plans to test different vaccine combinations that fight the flu, COVID-19, RSV, and human metapneumovirus. “The uniquely challenging year of 2020 for all of society proved to be an extraordinary proof-of-concept period for Moderna,” CEO Stéphane Bancel said in a news release. As part of its corporate update, Moderna said it had about $5.2 billion in cash as of Dec. 31, compared to the $1.2 billion in cash it had at the same time a year ago, and it expects to generate at least $11.7 billion in revenue in 2021 for its COVID-19 vaccine based on advance purchase agreements. Moderna’s stock has soared 489.1% over the last year, while the S&P 500
SPX,
-0.54%

is up 19.7%.

Let’s block ads! (Why?)


Source link

One Comment

  1. Elene Ardaly

    January 12, 2021 at 2:57 am

    I think other web site proprietors should take this web site as an model – very clean and magnificent style and design, in addition to the content. You are an expert in this area!

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

With obesity on the rise, the best diet may be tailored to our genes, experts say – ABC News

With the COVID-19 pandemic drawing more attention to America’s obesity problem, a gr…